Late outcome of 89 patients with soft-tissue sarcomas treated by surgery and three different radiotherapy schedules
Fiche publication
Date publication
décembre 2007
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BOREL Christian, Pr KURTZ Jean-Emmanuel, Pr NOEL Georges
Tous les auteurs :
Heymanna S, Jung GM, Simon P, Bergerat JP, Borel C, Di Marco A, Kurtz JE, Marcellin L, Ghnassia JP, Dufour P, Noel G
Lien Pubmed
Résumé
Purpose. - To evaluate the outcome of patients treated for soft tissue sarcoma using three different post-operative radiotherapy schedules. Methods and materials. - Between 1990 and 2003, 89 patients (median age 50.8 years) presenting with soft tissue sarcoma (located to the limbs for 66 of them) underwent post-conservative-surgery radiotherapy. Pathology was liposarcoma in 35 cases and 54 others tumors. Tumors grades (FNCLCC classification) were 1, 2, 3 or unknown in 29, 32, 19 and 9 cases, respectively. Surgery was considered as complete in 68 patients. Irradiation was normofractionated (NF) in 62 cases, hyperfractionated (BF) in 19 cases and hypofractionated (HF) in 8 cases. For all the patients, median delivered dose was 61 Gy [34-76 Gy]. Results. - Median follow-up of alive patients was 73,8 months [3-184]. Five-year local control (LC) and overall survival (OS) rates were 85.5 and 71.2% respectively. According to multifactorial analysis, favourable prognostic factors were for local control, complete surgery (P=0.0075) and for overall survival, complete surgery (P = 0.0267), grade 1 tumor (P = 0.012) and absence of distant recurrence (P = 0.0488). There was no statistical evidence of difference for the five-year LC and OS rates between the patients who received NF, BF or HF. There were few complications and there were comparable in the three groups. Conclusions. - This retrospective serie showed similar results for all the schedules. There is no evidence to recommend bifractionation. Hypofractionation should be used only in selected patients with poor performans status. (c) 2007 Elsevier Masson SAS. Tous droits reserves.
Référence
Cancer Radiother. 2007 Dec;11(8):443-51